On November 24, 2025, the FDA announced (here) that, following a comprehensive safety review, it has approved a reformulated ranitidine tablet, “marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during the product’s shelf-life.”

Ranitidine was the first product to be implicated in the nitrosamine impurity issue, which has impacted numerous products over the past five years and resulted not only in product recalls but also drug shortages as product shipments were often halted. The FDA and industry have expended considerable resources to identify the causes of the formation of nitrosamine impurities in a plethora of drug products. The results of the research have been tied to temperature and moisture as prime causes; there have also been evaluations of product formulations, including inactive ingredients and their contributory effects on nitrosamine formation.

With approval of the reformulated ranitidine product and its return to the market, the FDA has issued the following advice for patients who use ranitidine to ensure safe use of the product.

  • Keep Ranitidine Tablets in the original container (bottle) and protect from moisture.
  • After the first opening of the bottle, discard unused tablets after three months (ninety days) or by the expiration date on the bottle, whichever is sooner.
  • If more than one bottle is dispensed, open only one bottle at a time. Store additional bottles without opening until needed for dosing.
  • At the time of dosing, remove one tablet from the bottle. Immediately close the bottle, secure the cap, and keep the bottle tightly closed.
  • Keep the desiccant in the bottle.

These recommendations will be incorporated in revised labeling supporting the approval. In addition, the FDA advises patients who are taking alternate H2 blockers to consult with their healthcare providers prior to switching. The Agency also assures providers and patients that “the reformulated ranitidine maintains the same therapeutic effectiveness as previously approved products.”

The nitrosamine issue has plagued makers of numerous drug products since it was first recognized. Perhaps the reformulated product and revised labeling instructions will provide a path for others to reduce the industry’s heartburn over the nitrosamine issue.